Investment
Co-led TwoStep Therapeutics' oversubscribed $62.5M Series A alongside Insight Partners, coinciding with FDA IND clearance for lead program TS-104.
TwoStep Therapeutics
SEP 9, 2026
6 milestones· JAN 2026 – JUL 2026
Milestone
Synaptiq Therapeutics launched via acquisition of SYN-001 from Nobias Therapeutics, an MEC-majority-backed company; Nobias retains an equity stake in Synaptiq.
Synaptiq Therapeutics
JUL 23, 2026
Milestone
Portfolio company GC Therapeutics appointed Stefan Irion, MD, formerly of BlueRock Therapeutics, as Chief Scientific Officer.
GC Therapeutics
MAY 5, 2026
Milestone
Portfolio company Aspen Neuroscience reported positive 12-month safety and efficacy data from its ASPIRO Phase 1/2a Parkinson's cell therapy trial.
Aspen Neuroscience
MAR 18, 2026
Milestone
Portfolio company SonoThera presented new preclinical data on its RIPPLE nonviral gene-therapy delivery platform for Duchenne Muscular Dystrophy at MDA 2026.
SonoThera
MAR 5, 2026
Milestone
Portfolio company GC Therapeutics appointed former Blueprint Medicines CEO Kate Haviland as Board Chair and provided a pipeline update.
GC Therapeutics
JAN 9, 2026
Milestone
Portfolio company SonoThera launched a $125M Series B financing round at the 44th J.P. Morgan Healthcare Conference to advance its genetic medicine pipeline.
SonoThera
JAN 8, 2026